drugset / Trial / NCT04677179
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RandomizedParallel-groupDouble-blindTreatment
Summary
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
Timeline
- Start
- 2021-03-22
- Primary completion
- 2022-08-09
- Completion
- 2022-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezpegaldesleukin | Protein / enzyme biologic | — | Subcutaneous |